Castrate Resistant Prostate Cancer Market is Anticipated to Witness High Growth Due to Increasing Prevalence of Prostate Cancer
Castrate Resistant Prostate Cancer Market Castrate resistant prostate cancer is an advanced stage of prostate cancer that does not respond to androgen deprivation therapy. Increasing prevalence of prostate cancer and rising demand for advanced treatment options are major factors contributing to growth of the castrate resistant prostate cancer market. The Global Castrate Resistant Prostate Cancer Market Demand is estimated to be valued at US$ 12.82 billion in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period from 2024 to 2030. Prostate cancer is one of the most commonly occurring cancers in men. According to the National Cancer Institute, there were around 268,490 new cases of prostate cancer in the United States in 2022. Androgen deprivation therapy is the standard treatment for advanced prostate cancer. However, in many cases the cancer becomes resistant to androgen deprivation over time and continues to progress, leading to castrate resistant prostate cance